ATE301197T1 - Hybridinterferonzusammensetzungen und verfahren zu deren anwendung - Google Patents

Hybridinterferonzusammensetzungen und verfahren zu deren anwendung

Info

Publication number
ATE301197T1
ATE301197T1 AT97918591T AT97918591T ATE301197T1 AT E301197 T1 ATE301197 T1 AT E301197T1 AT 97918591 T AT97918591 T AT 97918591T AT 97918591 T AT97918591 T AT 97918591T AT E301197 T1 ATE301197 T1 AT E301197T1
Authority
AT
Austria
Prior art keywords
interferon
fusion polypeptides
polypeptide
segment
amino acid
Prior art date
Application number
AT97918591T
Other languages
English (en)
Inventor
Howard M Johnson
Prem S Subramaniam
Carol H Pontzer
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Application granted granted Critical
Publication of ATE301197T1 publication Critical patent/ATE301197T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97918591T 1996-04-12 1997-04-11 Hybridinterferonzusammensetzungen und verfahren zu deren anwendung ATE301197T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/631,328 US5939286A (en) 1995-05-10 1996-04-12 Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
PCT/US1997/006114 WO1997039127A1 (en) 1996-04-12 1997-04-11 Hybrid interferon compositions and methods of use

Publications (1)

Publication Number Publication Date
ATE301197T1 true ATE301197T1 (de) 2005-08-15

Family

ID=24530735

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97918591T ATE301197T1 (de) 1996-04-12 1997-04-11 Hybridinterferonzusammensetzungen und verfahren zu deren anwendung

Country Status (11)

Country Link
US (1) US5939286A (de)
EP (1) EP0914435B1 (de)
JP (1) JP2000508536A (de)
CN (2) CN100343282C (de)
AT (1) ATE301197T1 (de)
AU (1) AU718864B2 (de)
CA (1) CA2252082A1 (de)
DE (1) DE69733891T2 (de)
ES (1) ES2243990T3 (de)
TW (1) TW557301B (de)
WO (1) WO1997039127A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705363A (en) * 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
US6204022B1 (en) * 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
US6290297B1 (en) 1998-08-18 2001-09-18 Fisher Dynamics Corporation Latch assembly and seat hinge with interlock
US6833256B1 (en) 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them
CA2382989A1 (en) * 1999-08-27 2001-03-08 University Of Florida Materials and methods for inhibition of ige production
IL155730A0 (en) * 2000-11-03 2003-11-23 Biomedicines Inc Method for short-term and long-term drug dosimetry
CA2454860A1 (en) * 2001-08-12 2003-02-27 Pepgen Corporation Hybrid interferon/interferon tau proteins, compositions and methods of use
IL161889A0 (en) * 2001-11-09 2005-11-20 Biomedicines Inc Method for treating diseases with omega interferon
US20040126360A1 (en) * 2002-10-09 2004-07-01 Manning Mark C. Oral formulations for proteins and polypeptides
US8071322B2 (en) * 2002-11-12 2011-12-06 Epitomics, Inc. Method for identifying differentially expressed proteins
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CN1535724B (zh) * 2003-04-23 2012-09-05 北京金迪克生物技术研究所 重组人干扰素在制备预防严重性急性呼吸道综合征的药物的用途
EP1699920A4 (de) * 2003-12-31 2008-05-28 Centocor Inc Neue rekombinante proteine mit freiem n-terminalem thiol
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US7695710B2 (en) * 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
AU2006262151A1 (en) * 2005-06-20 2007-01-04 Pepgen Corporation Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
US20070243163A1 (en) * 2006-02-17 2007-10-18 Chih-Ping Liu Respiratory tract delivery of interferon-tau
EP2020990B1 (de) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
EP2157967B1 (de) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspensionsformulierungen insulinotroper peptide und ihre verwendung
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
EP3323423B1 (de) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN109293782A (zh) * 2014-01-08 2019-02-01 德益阳光生物技术（北京）有限责任公司 融合多肽及使用方法
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
WO2018204312A1 (en) * 2017-05-01 2018-11-08 Rutgers, The State University Of New Jersey Type i and type iii interferon fusion molecules and methods for use thereof
CN108840921B (zh) * 2018-05-31 2021-06-29 浙江善测禾骑士生物科技有限公司 羊α干扰素突变体及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016015B (en) * 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
US4460574A (en) * 1980-06-16 1984-07-17 Yabrov Alexander A Prophylaxis or treatment of interferon-sensitive diseases
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4507281A (en) * 1981-10-13 1985-03-26 Exovir, Inc. Interferon-containing compositions
WO1983002461A1 (en) * 1982-01-19 1983-07-21 Cetus Corp Multiclass hybrid interferons
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4892743A (en) * 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
EP0146903A3 (de) * 1983-12-19 1987-07-22 Schering Corporation Herstellung eines ein Hybrid-Interferon-Spezies kodierenden Vektors
US4636383A (en) * 1984-08-29 1987-01-13 Schering Corporation Interferon-cyclaradine combination
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
DE3607835A1 (de) * 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
US4846782A (en) * 1986-03-14 1989-07-11 Schering Corporation Treatment of cancer with interferon and radiotherapy
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
US5705363A (en) * 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
TW585911B (en) * 1992-10-30 2004-05-01 Univ Florida Ovine and bovine interferon TAU, compositions thereof and pharmaceutical uses thereof
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
US7056250B2 (en) * 2003-04-14 2006-06-06 The Goodyear Tire & Rubber Company Power transmission belt containing short high molecular weight polyacrylonitrile fiber

Also Published As

Publication number Publication date
EP0914435B1 (de) 2005-08-03
JP2000508536A (ja) 2000-07-11
WO1997039127A1 (en) 1997-10-23
US5939286A (en) 1999-08-17
DE69733891D1 (de) 2005-09-08
CN100343282C (zh) 2007-10-17
CN1221452A (zh) 1999-06-30
ES2243990T3 (es) 2005-12-01
CN1663963A (zh) 2005-09-07
CA2252082A1 (en) 1997-10-23
TW557301B (en) 2003-10-11
EP0914435A1 (de) 1999-05-12
CN1219796C (zh) 2005-09-21
AU2666197A (en) 1997-11-07
AU718864B2 (en) 2000-04-20
DE69733891T2 (de) 2006-06-01

Similar Documents

Publication Publication Date Title
DE69733891D1 (de) Hybridinterferonzusammensetzungen und verfahren zu deren anwendung
DE3854952D1 (de) Mykobakterielle rekombinanten und peptide
DK0670898T3 (da) Interleukin-3 (IL-3)-mutantpolypeptider
ES2009238A6 (es) Metodo para producir proteinas de mycobacterium tuberculosis y peptidos antigenicos de las mismas.
DE3166150D1 (en) N-(vinblastinoyl-23) derivatives of amino acids and peptides and their preparation
ATE402957T1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
ES8801517A1 (es) Un metodo para producir proteina tensioactiva alveolar
WO1994010313A3 (en) Interferon tau compositions and methods of use
HUT40072A (en) Process for producing diamino acid and peptide derivatives
PT666914E (pt) Nova proteina ligando da selectina p
WO2003016472A3 (en) Hybrid interferon/interferon tau proteins, compositions and methods of use
DE3686579D1 (en) Prokaryotisches expressionssystem.
EA200000685A1 (ru) Комплекс ifnar2/ifn
NO941415D0 (no) Polypeptider og deres anvendelse for å nöytralisere antistoffer
DE69233245D1 (de) Verfahren zur Herstellung von Peptiden
DE69532470D1 (de) Tri-, tetra-, penta- und polypeptide und ihre therapeutische verwendung als antidepressiva
DE68921674D1 (de) Peptide, deren Verwendung als Immuno-Suppressanten und Verfahren zu deren Herstellung.
DE3687405D1 (de) Aminosaeurederivate.
ATE135407T1 (de) Peptide, welche hiv-retroviren-hemmende antikörper induzieren, sowie gegen diese peptide gerichtete antikörper
Wolfenstein-Todel et al. Immunoglobulin A. Arrangement of disulfide bridges in the hinge region of an immunoglobulin A1 human myeloma protein
DK0946591T3 (da) Klonede glucagon-lignende peptid-2 receptorer
EP0723016A3 (de) Leukocyten-aktivierender Faktor
ATE112290T1 (de) Peptiden von retinblastoma gen produkten und antikoerper dagegen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties